Chief Commercial Officer Mitchell Micah converted options into 1,717 shares, increasing direct ownership by 0.93% to 185,815 units (SEC Form 4)

$MYO
Industrial Specialties
Health Care
Get the next $MYO alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mitchell Micah

(Last) (First) (Middle)
C/O MYOMO, INC.
45 BLUE SKY DR., SUITE 101

(Street)
BURLINGTON MA 01803

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MYOMO, INC. [ MYO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
06/09/2024
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/09/2024 M 1,717(1) A $0 185,815 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units $0 06/09/2024 M 1,717 06/09/2024 06/09/2024 Common Stock 1,717(2) $0 0 D
Explanation of Responses:
1. Represents vesting of performance-based restricted stock units granted under the Issuer's 2018 Stock Option and Incentive plan based on the relative stock price performance of the Company's common stock compared to a peer group of companies as measured from June 10, 2021 to March 9, 2024.
2. Represents performance-based restricted stock units granted under the Issuer's 2018 Stock Option and Incentive Plan. 1,717 shares were earned based on the Company's relative stock price performance compared to a peer group of companies from June 10, 2021 to March 9, 2024, which are reported in Table I of this report on Form 4. The remaining 9,683 restricted stock units granted expired unvested.
/s/ Micah Mitchell 01/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $MYO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MYO

DatePrice TargetRatingAnalyst
7/31/2024$7.00Buy
Craig Hallum
5/20/2024$7.00Buy
Lake Street
12/15/2023$6.50Buy
H.C. Wainwright
More analyst ratings

$MYO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

    $INGN
    $MDT
    $MYO
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Myomo, Inc. Prices $15.0 Million Public Offering of Common Stock

    Myomo, Inc. (NYSE:MYO) ("Myomo"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has priced an underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $5.00 per share. Myomo expects the gross proceeds from this offering to be approximately $15.0 million, before deducting the underwriting discount and other offering expenses. In connection with the offering, Myomo has granted the underwriter a 30-day option to purchase up to 450,000 additional shares of its common stock at the public offering price, less the underwriting discoun

    $MYO
    Industrial Specialties
    Health Care
  • Myomo, Inc. Announces Proposed Public Offering of Common Stock

    Myomo, Inc. (NYSE:MYO) ("Myomo"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In connection with the offering, Myomo also expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Craig-Hallum Capital Gr

    $MYO
    Industrial Specialties
    Health Care

$MYO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MYO
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$MYO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MYO
SEC Filings

See more

$MYO
Leadership Updates

Live Leadership Updates

See more
  • Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

    $INGN
    $MDT
    $MYO
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Myomo Appoints Heather Getz to its Board of Directors

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors. Ms. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership. She has significant expertise in finance, reimbursement, investor relations, compliance, M&A and strategic plannin

    $BFLY
    $MYO
    Medical Electronics
    Health Care
    Industrial Specialties
  • Myomo Appoints Yitzchak Jacobovitz to its Board of Directors

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective January 27, 2023, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has six directors. Mr. Jacobovitz, 47, is currently a partner and lead healthcare analyst at AIGH Capital Management and affiliates ("AIGH"), where he has significantly grown AIGH's healthcare footprint since joining in 2014. Prior to AIGH, Mr. Jacobovitz was a managing director at Capstone, a policy research

    $MYO
    Industrial Specialties
    Health Care

$MYO
Financials

Live finance-specific insights

See more
  • Myomo Reports Record Third Quarter Financial and Operating Results

    $9.2 million in revenue, raises full-year revenue guidance 225 MyoPro® authorizations and orders with 316 patients in backlog at quarter end 645 additions to the pipeline result in 1,263 patients in the pipeline as of September 30, 2024 Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and nine months ended September 30, 2024. Financial and operating highlights for the third quarter of 2024 include the following (all comparisons are with the third quarter of 2023 unless otherwise indicated): Pro

    $MYO
    Industrial Specialties
    Health Care
  • Myomo to Report Third Quarter Financial Results on November 6, 2024

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the third quarter ended September 30, 2024 on November 6, 2024. The Company will host a conference call the same day, Wednesday November 6, 2024 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PI

    $MYO
    Industrial Specialties
    Health Care
  • Myomo Reports Second Quarter 2024 Financial Results

    Record revenue of $7.5 million Record 213 MyoPro® authorizations and orders Record 550 additions to the pipeline, with 1,179 patients in the pipeline at quarter-end Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three and six months ended June 30, 2024. Financial and operational highlights for the second quarter of 2024 include the following (all comparisons are with the second quarter of 2023 unless otherwise indicated): Product revenue was $7.5 million, up 77%, with total revenue up 26% reflec

    $MYO
    Industrial Specialties
    Health Care

$MYO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more